{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:14:45Z","timestamp":1784970885037,"version":"3.55.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","award":["NCT01966666"],"award-info":[{"award-number":["NCT01966666"]}],"id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.cct.2021.106549","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T16:29:09Z","timestamp":1630168149000},"page":"106549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Current druggable targets for therapeutic control of Alzheimer's disease"],"prefix":"10.1016","volume":"109","author":[{"given":"Girdhari Lal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita Patil","family":"Samant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2021.106549_bb0005","first-page":"391","article-title":"Alzheimer\u2019s disease facts and figures","volume":"16","author":"Alzheimer\u2019\u2019s Association","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cct.2021.106549_bb0010","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2174\/1570159X15666170720095240","article-title":"Microglia and astrocytes in Alzheimer\u2019s disease: implications for therapy","volume":"16","author":"Fakhoury","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.cct.2021.106549_bb0015","first-page":"a006239","article-title":"Epidemiology of Alzheimer disease","volume":"2","author":"Mayeux","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.cct.2021.106549_bb0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","article-title":"Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers","volume":"88","author":"Reitz","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"2019","key":"10.1016\/j.cct.2021.106549_bb0025","first-page":"88","article-title":"Dementia collaborators, global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"GBD","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cct.2021.106549_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer\u2019s disease facts and figures","volume":"12","author":"Gaugler","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cct.2021.106549_bb0035","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid-beta: Structure, biology and structure-based therapeutic development","volume":"20","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.cct.2021.106549_bb0040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-Beta and Phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0045","first-page":"1","article-title":"Tau deposition is associated with functional isolation of the hippocampus in aging","author":"Harrison","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cct.2021.106549_bb0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neurobiolaging.2017.07.005","article-title":"Hippocampal neurophysiology is modified by a disease-associated C-terminal fragment of tau protein","volume":"60","author":"Tamagnini","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cct.2021.106549_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ijdevneu.2004.07.013","article-title":"Amyloid-induced neurofibrillary tangle formation in Alzheimer\u2019s disease: insight from transgenic mouse and tissue-culture models","volume":"22","author":"G\u00f6tz","year":"2004","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-015-1449-5","article-title":"Analyzing dendritic spine pathology in Alzheimer\u2019s disease: problems and opportunities","volume":"130","author":"Dorostkar","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cct.2021.106549_bb0065","doi-asserted-by":"crossref","first-page":"a006148","DOI":"10.1101\/cshperspect.a006148","article-title":"The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment","volume":"2","author":"Tarawneh","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.cct.2021.106549_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/3740461","article-title":"Current Concepts of Neurodegenerative Mechanisms in Alzheimer\u2019s Disease","volume":"22","author":"Magalingam","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.cct.2021.106549_bb0075","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-161088","article-title":"Oxidative stress, synaptic dysfunction, and alzheimer\u2019s disease","volume":"57","author":"T\u00f6nnies","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tips.2004.12.010","article-title":"A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer\u2019s disease?","volume":"26","author":"Francis","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cct.2021.106549_bb0085","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2012.02.040","article-title":"Alzheimer mechanisms and therapeutic strategies","volume":"148","author":"Huang","year":"2012","journal-title":"Cell."},{"key":"10.1016\/j.cct.2021.106549_bb0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4161\/cam.5.4.16986","article-title":"The roles of amyloid precursor protein (APP) in neurogenesis, implications to pathogenesis and therapy of Alzheimer's Disease (AD)","volume":"5","author":"Zhou","year":"2011","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.cct.2021.106549_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/celldisc.2016.26","article-title":"Alzheimer\u2019s disease-associated mutations increase amyloid precursor protein resistance to \u03b3-secretase cleavage and the A\u03b242\/A\u03b240 ratio","volume":"2","author":"Xu","year":"2016","journal-title":"Cell Discov."},{"key":"10.1016\/j.cct.2021.106549_bb0100","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00018-017-2463-7","article-title":"Clearance of cerebral A\u03b2 in Alzheimer\u2019s disease: reassessing the role of microglia and monocytes","volume":"74","author":"Zuroff","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cct.2021.106549_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1139\/jpn.0442","article-title":"Interactions between \u03b2-amyloid and central cholinergic neurons: Implications for Alzheimer\u2019s disease","volume":"29","author":"Kar","year":"2004","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3233\/JAD-2011-102097","article-title":"Effect of neocortical and hippocampal amyloid deposition upon galaninergic and cholinergic neurites in A\u03b2PPswe\/PS1\u0394E9 mice","volume":"25","author":"Kelley","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fncel.2018.00487","article-title":"NGF-dependent changes in ubiquitin homeostasis trigger early cholinergic degeneration in cellular and animal AD-model","volume":"12","author":"Latina","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","article-title":"An overview of APP processing enzymes and products","volume":"12","author":"Chow","year":"2010","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.cct.2021.106549_bb0125","doi-asserted-by":"crossref","first-page":"77sr1","DOI":"10.1126\/scitranslmed.3002369","article-title":"Alzheimer\u2019s disease: The challenge of the second century","volume":"3","author":"Holtzman","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cct.2021.106549_bb0130","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.15252\/embj.201797397","article-title":"APP mouse models for Alzheimer\u2019s disease preclinical studies","volume":"36","author":"Sasaguri","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.cct.2021.106549_bb0135","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"\u03b3-Secretase inhibitors and modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.cct.2021.106549_bb0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2021.106549_bb0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.celrep.2017.09.032","article-title":"Semagacestat Is a Pseudo-Inhibitor of \u03b3-Secretase","volume":"21","author":"Tagami","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.cct.2021.106549_bb0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cct.2021.106549_bb0155","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802611795860942","article-title":"\u03b3-Secretase inhibitors and modulators for the treatment of Alzheimer\u2019s disease: disappointments and hopes","volume":"11","author":"Imbimbo","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.cct.2021.106549_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jcpt.12112","article-title":"Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches","volume":"39","author":"Mikulca","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.cct.2021.106549_bb0165","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","article-title":"Alzheimer\u2019s disease drug development pipeline: 2017","volume":"3","author":"Cummings","year":"2017","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.cct.2021.106549_bb0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nrl.2015.03.012","article-title":"Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein","volume":"33","author":"Folch","year":"2018","journal-title":"Neurologia."},{"key":"10.1016\/j.cct.2021.106549_bb0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-017-0093-5","article-title":"Role of BACE1 in Alzheimer\u2019s synaptic function","volume":"6","author":"Das","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.cct.2021.106549_bb0180","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","article-title":"Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease","volume":"28","author":"Imbimbo","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.cct.2021.106549_bb0185","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2021.106549_bb0190","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1172\/JCI21746","article-title":"Amyloid at the cutting edge: activation of \u03b1-secretase prevents amyloidogenesis in an Alzheimer disease mouse model","volume":"113","author":"Lichtenthaler","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2021.106549_bb0195","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000334300","article-title":"Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein","volume":"10","author":"Holthoewer","year":"2012","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0200","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00001813-200208000-00001","article-title":"The clinical development of the bryostatins","volume":"13","author":"Clamp","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.cct.2021.106549_bb0205","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3233\/JAD-170161","article-title":"Bryostatin effects on cognitive function and PKC\u03f5 in Alzheimer\u2019s disease phase IIa and expanded access trials","volume":"58","author":"Nelson","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0210","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/jnc.12202","article-title":"Alzheimer\u2019s A\u03b242 and A\u03b240 peptides form interlaced amyloid fibrils, 6 J","volume":"126","author":"Gu","year":"2013","journal-title":"Neurochem."},{"key":"10.1016\/j.cct.2021.106549_bb0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of Tramiprosate in development for the treatment of Alzheimer\u2019s disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cct.2021.106549_bb0220","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/BF03654836","article-title":"The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review","volume":"24","author":"Marchionni","year":"2012","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.cct.2021.106549_bb0225","first-page":"219","article-title":"Clinical Benefits of Tramiprosate in Alzheimer\u2019s Disease Are Associated with Higher Number of APOE4 Alleles: The \u201cAPOE4 Gene-Dose Effect\u201d","volume":"3","author":"Abushakra","year":"2016","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0230","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12603-009-0065-2","article-title":"New insights into a clinical trial for colostrininTM in Alzheimer\u2019s disease","volume":"13","author":"Szaniszlo","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.cct.2021.106549_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-0580-2","article-title":"Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer\u2019s disease","volume":"12","author":"Yoshida","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.cct.2021.106549_bb0240","doi-asserted-by":"crossref","DOI":"10.1080\/13543784.2020.1795127","article-title":"Discontinued disease-modifying therapies for Alzheimer\u2019s disease: status and future perspectives","author":"Imbimbo","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.cct.2021.106549_bb0245","series-title":"Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer\u2019s Disease","author":"Panza","year":"2016"},{"key":"10.1016\/j.cct.2021.106549_bb0250","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1476-5381.2011.01713.x","article-title":"Tau-targeted treatment strategies in Alzheimer\u2019s disease","volume":"165","author":"G\u00f6tz","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cct.2021.106549_bb0255","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1385\/NMM:2:2:151","article-title":"Axonal transport, tau protein, and neurodegeneration in Alzheimer\u2019s disease","volume":"2","author":"Terwel","year":"2002","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.cct.2021.106549_bb0260","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer\u2019s disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cct.2021.106549_bb0265","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3\u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0270","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.brainresbull.2017.05.006","article-title":"Cyclin-dependent kinase 5: a novel avenue for Alzheimer\u2019s disease","volume":"132","author":"Bhounsule","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.cct.2021.106549_bb0275","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1007\/s12035-015-9369-x","article-title":"The role of Cdk5 in Alzheimer\u2019s disease","volume":"53","author":"Liu","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.cct.2021.106549_bb0280","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/1381612822666151124235028","article-title":"Neuroprotective mechanisms mediated by CDK5 inhibition","volume":"22","author":"Mushtaq","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cct.2021.106549_bb0285","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jm3017317","article-title":"Progress and developments in tau aggregation inhibitors for Alzheimer disease","volume":"56","author":"Bulic","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cct.2021.106549_bb0290","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fnagi.2019.00256","article-title":"The evolution of tau phosphorylation and interactions","volume":"11","author":"Trushina","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0295","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cct.2021.106549_bb0300","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of Low Dose Leuco-Methylthioninium 2Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer\u2019s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0305","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.phrs.2010.12.002","article-title":"The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer\u2019s disease and related tauopathies","volume":"63","author":"Brunden","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cct.2021.106549_bb0310","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1523\/JNEUROSCI.2357-10.2010","article-title":"A oligomers cause localized Ca2+ elevation, Missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines","volume":"30","author":"Zempel","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model","volume":"102","author":"Zhang","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cct.2021.106549_bb0320","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1172\/JCI0215451","article-title":"Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo","volume":"110","author":"Fellner","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2021.106549_bb0325","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of Tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0330","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cct.2021.106549_bb0335","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","volume":"88","author":"Relkin","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.cct.2021.106549_bb0340","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","article-title":"Tau immunotherapy for Alzheimer\u2019s disease","volume":"21","author":"Pedersen","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.cct.2021.106549_bb0345","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuropharm.2010.02.010","article-title":"Neurochemical basis for symptomatic treatment of Alzheimer\u2019s disease","volume":"59","author":"Francis","year":"2010","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.cct.2021.106549_bb0350","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3233\/JAD-161118","article-title":"Therapeutics of neurotransmitters in Alzheimer\u2019s disease","volume":"57","author":"Kandimalla","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0355","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnins.2019.00038","article-title":"Innovative therapy for Alzheimer\u2019s disease-with focus on biodelivery of NGF","volume":"13","author":"Mitra","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0360","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer\u2019s therapeutics (review)","author":"Sharma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cct.2021.106549_bb0365","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.2174\/1381612825666191008103141","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease: multitargeting strategy based on anti-Alzheimer\u2019s drugs repositioning","volume":"25","author":"Kabir","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cct.2021.106549_bb0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2019.00043","article-title":"The role of NMDA receptors in Alzheimer\u2019s disease","volume":"13","author":"Liu","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0375","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nn.2583","article-title":"Amyloid-\u0392-induced neuronal dysfunction in Alzheimer\u2019s disease: from synapses toward neural networks","volume":"13","author":"Palop","year":"2010","journal-title":"Nat. Neurosci."},{"issue":"2018","key":"10.1016\/j.cct.2021.106549_bb0380","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-170672","article-title":"Memantine for the treatment of dementia: a review on its current and future applications, J","volume":"62","author":"Folch","year":"2018","journal-title":"Alzheimer Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0385","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41398-018-0201-z","article-title":"Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer\u2019s disease","volume":"8","author":"Okamoto","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.cct.2021.106549_bb0390","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.nurt.2008.05.002","article-title":"Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer\u2019s disease","volume":"5","author":"Fisher","year":"2008","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.cct.2021.106549_bb0395","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41386-018-0168-8","article-title":"TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects","volume":"44","author":"Sako","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.cct.2021.106549_bb0400","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1440-1681.1999.03151.x","article-title":"The \u201cABC\u201d of GABA receptors: a brief review","volume":"26","author":"Chebib","year":"1999","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.cct.2021.106549_bb0405","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1113\/jphysiol.2003.042556","article-title":"Enhanced GABAA receptor-mediated activity following activation of NMDA receptors in Cajal-Retzius cells in the developing mouse neocortex","volume":"550","author":"Chan","year":"2003","journal-title":"J. Physiol."},{"issue":"2016","key":"10.1016\/j.cct.2021.106549_bb0410","first-page":"31","article-title":"Implications of GABAergic neurotransmission in Alzheimer\u2019s disease, front","volume":"8","author":"Li","year":"2016","journal-title":"Aging Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0415","first-page":"1479","article-title":"SGS742: the first GABAB receptor antagonist in clinical trials, Biochem","volume":"68","author":"Froestl","year":"2004","journal-title":"Pharmacol."},{"key":"10.1016\/j.cct.2021.106549_bb0420","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fncel.2014.00203","article-title":"Frontiers in therapeutic development of allopregnanolone for Alzheimer\u2019s disease and other neurological disorders","volume":"8","author":"Irwin","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0425","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2119\/molmed.2010.00180","article-title":"Selective antihypertensive dihydropyridines lower A\u03b2 accumulation by targeting both the production and the clearance of A\u03b2 across the blood-brain barrier","volume":"17","author":"Paris","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.cct.2021.106549_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial","volume":"15","author":"Lawlor","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.cct.2021.106549_bb0435","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fncel.2014.00112","article-title":"Neuroinflammation in the pathogenesis of Alzheimer\u2019s disease. A rational framework for the search of novel therapeutic approaches","volume":"8","author":"Morales","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0440","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/nn1997","article-title":"Microglia: active sensor and versatile effector cells in the normal and pathologic brain","volume":"10","author":"Hanisch","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0445","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","article-title":"Microglia: a sensor for pathological events in the CNS","volume":"19","author":"Kreutzberg","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0450","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neuroscience.2012.04.050","article-title":"Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation","volume":"216","author":"Liu","year":"2012","journal-title":"Neuroscience."},{"key":"10.1016\/j.cct.2021.106549_bb0455","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-017-0355-7","article-title":"Drug candidates in clinical trials for Alzheimer\u2019s disease","volume":"24","author":"Hung","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.cct.2021.106549_bb0460","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2014.10.029","article-title":"CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid","volume":"302","author":"Porrini","year":"2015","journal-title":"Neuroscience."},{"key":"10.1016\/j.cct.2021.106549_bb0465","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/14737175.2015.955853","article-title":"Strategy to reduce free radical species in Alzheimer\u2019s disease: an update of selected antioxidants","volume":"15","author":"Di Domenico","year":"2014","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.cct.2021.106549_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2016.07.005","article-title":"Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson\u2019s disease and Alzheimer\u2019s disease","volume":"147","author":"Jiang","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.cct.2021.106549_bb0475","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archneurol.2010.144","article-title":"Dietary antioxidants and long-term risk of dementia","volume":"67","author":"Devore","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cct.2021.106549_bb0480","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1001\/jama.287.24.3223","article-title":"Dietary intake of antioxidants and risk of Alzheimer disease","volume":"287","author":"Engelhart","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.cct.2021.106549_bb0485","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1001\/jama.287.24.3230","article-title":"Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study","volume":"287","author":"Morris","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.cct.2021.106549_bb0490","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.13031","article-title":"Vitamin B1 (thiamine) and dementia","volume":"1367","author":"Gibson","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.cct.2021.106549_bb0495","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0959-4388(00)00092-1","article-title":"Neurotrophin signal transduction in the nervous system","volume":"10","author":"Kaplan","year":"2000","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.cct.2021.106549_bb0500","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00005-015-0376-4","article-title":"Neurotrophic factors and their potential applications in tissue regeneration","volume":"64","author":"Xiao","year":"2016","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.cct.2021.106549_bb0505","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12031-009-9238-z","article-title":"Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation","author":"Cuello","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0510","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/NEN.0b013e3181aed9e6","article-title":"Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease","volume":"68","author":"Bruno","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.cct.2021.106549_bb0515","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0169-328X(97)00125-3","article-title":"Brain-derived neurotrophic factor is reduced in Alzheimer\u2019s disease","volume":"49","author":"Connor","year":"1997","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.cct.2021.106549_bb0520","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00005072-199907000-00007","article-title":"BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies","volume":"58","author":"Ferrer","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.cct.2021.106549_bb0525","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.18632\/aging.101518","article-title":"A promising connection between BDNF and Alzheimer\u2019s disease","volume":"10","author":"Giuffrida","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.cct.2021.106549_bb0530","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archneur.57.6.846","article-title":"Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas","volume":"57","author":"Hock","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cct.2021.106549_bb0535","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrd3366","article-title":"Potential therapeutic uses of BDNF in neurological and psychiatric disorders","volume":"10","author":"Nagahara","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cct.2021.106549_bb0540","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-130716","article-title":"Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer\u2019s disease in the absence of apolipoprotein E4 allele","volume":"37","author":"Qiu","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cct.2021.106549_bb0545","doi-asserted-by":"crossref","first-page":"9760","DOI":"10.1074\/jbc.RA118.006420","article-title":"A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer\u2019s disease pathology in mice","volume":"294","author":"Liu","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cct.2021.106549_bb0550","first-page":"1","article-title":"Novel therapeutic strategies for Alzheimer\u2019s disease targeting brain cholesterol homeostasis","volume":"00","author":"Samant","year":"2020","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.cct.2021.106549_bb0555","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2174\/1567205014666171016101816","article-title":"Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer\u2019s Disease Dementia","volume":"15","author":"de Oliveira","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.cct.2021.106549_bb0560","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s12031-020-01588-7","article-title":"Selected LDLR and APOE polymorphism affect cognitive and functional response to lipophilic statins in Alzheimers disease","volume":"70","author":"de Oliveira","year":"2020","journal-title":"J. Mol. Neurosci."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421002858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421002858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:54:16Z","timestamp":1761555256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714421002858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":112,"alternative-id":["S1551714421002858"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2021.106549","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current druggable targets for therapeutic control of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2021.106549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106549"}}